Antibiotic combinations for enterococcus blood infection
Part of Blood & lymphatic, Infections clinical trials.
This study looks at whether using two or more antibiotics together works better than one alone for a specific type of blood infection caused by Enterococcus faecalis bacteria. The goal is to find the safest and most effective way to treat this infection and improve outcomes for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a blood infection caused only by Enterococcus faecalis bacteria (no other germs).
- You have taken at least one antibiotic (like ampicillin, vancomycin, or daptomycin) for 5 or more days, with or without a second drug.
- You agree to be part of the study and sign a consent form.
- You are not expected to pass away within the next 3 days from the infection.
- You do not have any other active infection besides the blood infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.
This trial tests a new antibiotic combination, cefepime/enmetazobactam, against standard therapy for people with complicated urinary tract infections that have spread to the bloodstream. It aims to see if the new drug works better and is safe.
This study tests a careful antibiotic-use program for patients with a bloodstream infection caused by a group of bacteria called Enterobacterales. The goal is to use the right antibiotics for the right amount of time. It may help you get better treatment with fewer side effects.
This trial looks at how well certain penicillin-type antibiotics work for treating a bloodstream infection caused by a bacterium called Enterococcus faecalis. It may help doctors know which treatment is best for patients with this infection.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
This trial tests whether the antibiotic cefotetan works as well as or better than standard treatments for E. coli bloodstream infections. You may be eligible if you have a confirmed E. coli infection in your blood that started in your urinary or genital area, and you have just started antibiotics in the hospital.
Hear when a new Enterococcus Faecalis Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.